SARS-CoV-2 Nsp1 protein effectively blocks host antiviral defenses


July 20, 2020 -- SARS-CoV-2 Nsp1 protein effectively blocks host antiviral defenses

 SARS-CoV-2 Nsp1 protein effectively blocks host antiviral defenses
 
Web version

scienceboard.net
July 20, 2020
Top Stories
SARS-CoV-2 Nsp1 protein effectively blocks host antiviral defenses
A SARS-CoV-2 protein, Nsp1, may play a critical role in weakening antiviral innate immune defenses, according to a study published in Science on July 17. Researchers identified how the viral protein specifically shuts down host protein production and subsequently blocks host immune functions.  

 
Sorrento plans phase II trial for COVID-19 treatment
Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment of moderate and severe COVID-19 patients.  

 
Pfizer, BioNTech release clinical data for COVID-19 vaccine candidate
Pfizer and BioNTech have released initial data from an ongoing phase I/II clinical trial for the COVID-19 messenger RNA-based vaccine candidate, BNT162b1.  

 


Cancer & Disease Research
SARS-CoV-2 Nsp1 protein effectively blocks host antiviral defenses
A SARS-CoV-2 protein, Nsp1, may play a critical role in weakening antiviral innate immune defenses, according to a study published in Science on July 17. Researchers identified how the viral protein specifically shuts down host protein production and subsequently blocks host immune functions.  

 
New guidance released on genetic testing for dyslipidemia patients
The National Lipid Association has released an official scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia.  

 
Cell Biology
The race is on to create a COVID-19 vaccine. But what next?
Fears of continuing waves of infection with the SARS-CoV-2 virus have helped trigger an accelerated effort among drug developers to bring a coronavirus vaccine to market. But even after a vaccine is developed and approved, there are a host of other challenges that must be solved to make sure it is administered widely enough to protect society at large.  

 
Drug Discovery & Development
Sorrento plans phase II trial for COVID-19 treatment
Sorrento Therapeutics received clearance from the U.S. Food and Drug Administration to initiate a phase II clinical trial evaluating abivertinib for treatment of moderate and severe COVID-19 patients.  

 
Red blood cells offer potential to deliver vaccines
Scientists have developed a biomimetic vaccine-delivery strategy based on an innate immune function of red blood cells that can deliver vaccine nanoparticles to the spleen, according to a research article published in the Proceedings of the National Academy of Sciences on July 14.  

 
Immunology
Pfizer, BioNTech release clinical data for COVID-19 vaccine candidate
Pfizer and BioNTech have released initial data from an ongoing phase I/II clinical trial for the COVID-19 messenger RNA-based vaccine candidate, BNT162b1.  

 
Thermo Fisher expands COVID-19 therapies, vaccines
Thermo Fisher Scientific is expanding the development and production of COVID-19 vaccines, therapies, and additional treatments.  

 
Life Science Informatics
Fox Chase creates AI program for virtual drug screening
Fox Chase Cancer Center researchers have developed a new machine-learning program that could make virtual screening for cancer drugs more effective. Their findings were published July 15 in the Proceedings of the National Academy of Sciences of the United States of America.  

 
What Your Colleagues are Buzzing About
Childhood vaccines may help protect against COVID-19 mortality
  
Scientists urge that surveillance of a new SARS-CoV-2 variant is necessary
  



• Do not reply to this e-mail as it was sent automatically from an unmonitored account.
  
•Unsubscribe from the Letter from the Editor.
  
•Reset your password.
  
•Contact scienceboard.net support.
  
•scienceboard.net Privacy Policy.
  
•Email sent to: .

scienceboard.net, 1350 North Kolb Road, Suite 215, Tucson, AZ 85715 USA - +1 520-298-1000
Copyright 2020 scienceboard.net. All Rights Reserved.
 
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.